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required a discount greater than 61% and 71%, respectively,
from the branded WAC to achieve cost per unit of LDL-C reduc-
tion lower than generic lovastatin. CONCLUSION: To facilitate
effective and efﬁcient management of patients with dyslipidemia,
a tiered formulary could include generic simvastatin or pravas-
tatin as the cost-effective generic statin in the ﬁrst tier (depend-
ing upon level of discount to current WAC) and rosuvastatin as
the cost-effective branded statin in the second tier.
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OBJECTIVES: Clinical evidence suggests that achieving recom-
mended HDL-C levels reduces the likelihood of CHD events and
mortality. The beneﬁts of standard fenoﬁbrate formulation 
on HDL-C and triglyceride levels (TG) are well established;
however, full beneﬁts have typically required administration with
food. Furthermore, evidence suggests that as many as 30% of
people do not comply with food requirements. A new formula-
tion of fenoﬁbrate (fenoﬁbrate 145) that does not require admin-
istration with food has been developed. A cost-effectiveness
model was developed to determine the incremental cost of
meeting additional recommended lipid levels when fenoﬁbrate
145 is substituted for a standard fenoﬁbrate formulation 
that requires food administration in a diabetic population.
METHODS: A simulation model using a managed care per-
spective was designed to predict changes in lipid levels [HDL-C,
LDL-C, TG, and total cholesterol (TC)] and associated drug
costs based on Wholesale Acquisition Costs over the course of
1 year. Lipid targets were based on NCEP-ATP III. A hypothet-
ical cohort of 1000 was modeled for a diabetic population with
abnormal lipid levels based on NHANES data. Lipid changes
were based on the study of fenoﬁbrate by Athyros, et al. 2002.
A reduction in efﬁcacy for each lipid parameter, based on previ-
ously reported work, was applied against patients on standard
fenoﬁbrate therapy (requiring food co-administration).
RESULTS: In a cohort of 1000 patients, substituting fenoﬁbrate
145 for standard fenoﬁbrate therapy resulted in 9.4% more dia-
betic patients reaching TG targets. Seventy-two more patients
(11% increase) on fenoﬁbrate 145 achieved at least 2 targets and
27 more patients (18% increase) achieved at least 3 targets. The
incremental 1 year cost per additional patient reaching TG
targets was $0.78. CONCLUSION: Substituting a non-food
requiring fenoﬁbrate for a standard fenoﬁbrate increases the
number of patients achieving TG and multiple target goals at 1
year at a low cost.
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OBJECTIVES: Previous studies have examined the association
between depression and hypertension. This study aims to
examine whether health status and health care costs differ
between hypertensive patients with and without depression.
METHODS: The study sample was all adult survey respondents
with a self-reported diagnosis of hypertension from the MEPS
(2002–2003). These respondents were also asked about the pres-
ence of conditions related to depression. Health status measures
include SF-12 physical component summary (PCS) and SF-12
mental component summary (MCS) score, and EQ-5D utility
score. Health care utilization was explored in the following cat-
egories: outpatient, inpatient, dental, and pharmacy. The impact
of depression on health status or health care utilization was
explored using multivariate linear regression models with depres-
sion as an independent dummy variable, after controlling for age,
gender, ethnicity, marital status, income, and health insurance.
All analyses are weighted to the US population by the personal
level weights reported in the MEPS data set. RESULTS: Among
a total of 5052 MEPS respondents having hypertension, 1962
reported having (38.84%) depression problems. These two
groups (with and without depression) were comparable in age
and ethnicity. Female hypertensive patients with lower income
level or with Medicare or Medicaid coverage had a higher 
proportion of depression. In regression models, hypertensive
patients with depression had worse health status: SF-12 PCS
score (−5.6, p < 0.0001), SF-12 MCS score (−13.5, p < 0.0001),
and EQ-5D utility score (−0.20, p < 0.0001). Hypertensive
patients with depression had higher utilization of outpatient
($415, p < 0.0001) and pharmacy ($10, p < 0.0001) services, but
both groups had comparable expenditures in inpatient care
($0.09, p < 0.0001) and dental service (−$23, p > 0.05). CON-
CLUSION: In the U.S. population, hypertensive patients with
depression had poorer health status and higher health care
expenditure in outpatient services and prescription drug com-
pared with those without depression. The difference in inpatient
cost between these groups was very small.
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OBJECTIVES: Using recent US national claims data, this study
examined characteristics of managed care patients taking clopi-
dogrel in outpatient settings and analyzed patterns of use.
METHODS: This retrospective study identiﬁed patients with
oral antiplatelet claims in a large, national, managed care claims
database (Pharmetrics) between 1/2003–6/2006 (n = 47,364). All
medical and pharmacy claims were analyzed during this period.
Analysis focused on outpatient use patterns of clopidogrel and
patient characteristics, e.g., demographics, comorbidities, inpa-
tient history, and other cardiovascular medication use. Aspirin
therapy was not available in the prescription claims data.
RESULTS: Clopidogrel was the most widely prescribed
antiplatelet, representing 93% of all prescriptions. Men repre-
sented 65% of the patients taking clopidogrel. The mean age was
56.9 years, with 69% of individuals aged 50 to 65 years. The
most common outpatient diagnoses were essential hypertension
(61%), unspeciﬁed hyperlipidemia (57%), hypercholesterolemia
(44%), and unspeciﬁed chest pain (43%). On average, users of
clopidogrel had 3.41 prescriptions per month in 2006 at a health
plan cost of $376.50/month. Average length of therapy for clopi-
dogrel was 292 days. By patient type, it varied from 283 days
for coronary artery bypass surgery, 336 days for percutaneous
coronary intervention (PCI), and 344 days for stroke. However,
10.4% of PCI patients took clopidogrel for ≤30 days. Patients
reﬁlled their clopidogrel prescriptions for 93% of the daily
regimen needed during therapy. Frequent concomitant cardiac
medications included statins (63.9%), beta-blockers (55.0%),
ACE-inhibitors (48.7%), and diuretics (14.2%). Data show that
40–50% of patients discontinued another concomitant cardiac
